“…While surgical replacement of the infected valvular tissue remains the primary treatment [19], the surgical community has been debating the best option for an aortic substitute, whether it should be a conventional xenograft or mechanical prosthesis, or allogenic or autologous tissues for decades. Several variables, such as the patient's age, risk factors, comorbidities, and contraindications to anticoagulation, as well as anatomopathological factors such as the extent of the infection and pathogen virulence, the timing of intervention, and specific features of the aortic substitute used such as durability and risk of infection recurrence, require prompt assessment during the decision-making process for surgical treatment of IE [40][41][42][43][44][45][46][47][48][49][50][51].…”